Velcade Approved for Mantle Cell Lymphoma in Europe

The European Commission approved the drug Velcade (bortezomib) for the treatment of adults with previously untreated mantle cell lymphoma (MCL).

Velcade had previously only been approved for the treatment of multiple myeloma.

This latest indication is specifically for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CAP, or VR-CAP when Velcade is included) in treatment-naive patients who are deemed unsuitable for a blood stem cell transplantation.

Previous trial led to drug's approval

Approval was based on data from LYM-3002, a random and controlled Phase III trial that included 487 patients diagnosed with mantle cell lymphoma who were not eligible for a transplantation. The trial pitted VR-CAP against R-CHOP.

"We are delighted that the European Commission has approved extending the indications for use of Velcade to include first-line therapy for patients with mantle cell lymphoma," said Thomas Stark, Janssen EMEA Vice President of Medical Affairs. "We already offer Imbruvica as a second-line treatment in MCL and are pleased to be able to provide additional treatment options for this disease to patients and physicians."

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...